Business
Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2022
Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2022.
About this update from Avivagen, Inc.
[{"type":"text","content":"\nAvivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2022.\n\nThird Quarter July 31, 2022, Financial Results\n\nThe Company’s unaudited Financial Statements for the third quarter ended July 31, 2022, and the accompanying Management’s Discussion and Analysis have been filed on the System for Electronic Document Analysis and Retrieval and are available via its website (www.sedar.com). The financial information for the third quarter ended July 31, 2022, should be read in conjunction with the Company’s unaudited Financial Statements as well as its Management’s Discussion and Analysis for the third quarter ended July 31, 2022\n\nThe Company reported net revenues of $48,606 and a comprehensive loss of $(1,901,453) for the three-month period ended July 31, 2022. This compares to revenues of $878,811 and a comprehensive loss of $(1,209,130) in the three-month period ended July 31, 2021.\n\nFor the nine-month period ended July 31, 2022, the Company reported net revenues of $408,201 and a comprehensive loss of $(4,757,982). This compares to revenues of $1,300,412 and a comprehensive loss of $(4,673,079) in the nine-month period ended July 31, 2021.\n\nAs at July 31, 2022, the Company reported total assets of $1,660,004 (current assets of $1,545,391), total liabilities of $6,920,903, and shareholders’ deficit of $(5,260,899).\n\nThe company also announced the appointment of Mr. Ira Levy as interim CFO, effective immediately. Mr. Levy has over 15 years of experience in a wide range of high-growth, early-stage companies, both public and private, with an MBA from the Schulich School of Business in addition to his professional designation as a Chartered Accountant.\n\nAbout Avivagen\nAvivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol V...